Evidence map›Paper›PMID 38170638›Full record

ArticlemAbs

Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function.

Jennifer L Schwedler, Maxwell A Stefan, Christine E Thatcher, Peter R McIlroy, Anupama Sinha, Ashlee M Phillips, Christopher A Sumner, Colleen M Courtney, Christina Y Kim, Dina R Weilhammer and 1 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Jennifer L SchwedlerBiotechnology and Bioengineering Department, Sandia National Laboratories, Livermore, CA, USA.
Maxwell A StefanBiotechnology and Bioengineering Department, Sandia National Laboratories, Livermore, CA, USA.
Christine E ThatcherBiotechnology and Bioengineering Department, Sandia National Laboratories, Livermore, CA, USA.
Peter R McIlroyBiotechnology and Bioengineering Department, Sandia National Laboratories, Livermore, CA, USA.
Anupama SinhaBiotechnology and Bioengineering Department, Sandia National Laboratories, Livermore, CA, USA.
Ashlee M PhillipsBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.
Christopher A SumnerBiotechnology and Bioengineering Department, Sandia National Laboratories, Livermore, CA, USA.
Colleen M CourtneyBiotechnology and Bioengineering Department, Sandia National Laboratories, Livermore, CA, USA.
Christina Y KimBiotechnology and Bioengineering Department, Sandia National Laboratories, Livermore, CA, USA.
Dina R WeilhammerBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.
Brooke HarmonBiotechnology and Bioengineering Department, Sandia National Laboratories, Livermore, CA, USA.ORCID 0000-0003-0621-5320
Sandia National Laboratories California · USLawrence Livermore National Laboratory · US

Funding

the Defense Threat Reduction Agency CONTRACT HDTRA140027, PROJECT CB10489, PI: HARMON
6 · The paper itself

Abstract

The development of specific, safe, and potent monoclonal antibodies (Abs) has led to novel therapeutic options for infectious disease. In addition to preventing viral infection through neutralization, Abs can clear infected cells and induce immunomodulatory functions through engagement of their crystallizable fragment (Fc) with complement proteins and Fc receptors on immune cells. Little is known about the role of Fc effector functions of neutralizing Abs in the context of encephalitic alphavirus infection. To determine the role of Fc effector function in therapeutic efficacy against Venezuelan equine encephalitis virus (VEEV), we compared the potently neutralizing anti-VEEV human IgG F5 (hF5) Ab with intact Fc function (hF5-WT) or containing the loss of function Fc mutations L234A and L235A (hF5-LALA) in the context of VEEV infection. We observed significantly reduced binding to complement and Fc receptors, as well as differential

Indexed as

Antibodies, ViralEncephalitis Virus, Venezuelan EquineAnimalsAntibodies, NeutralizingHorsesHumansImmunoglobulin GReceptors, FcAntibodies, NeutralizingAntibodies, ViralImmunoglobulin GReceptors, FcAntibody dependent cell-mediated cytotoxicity (ADCC)antibody therapycomplementcomplement dependent cytotoxicity (CDC)Fc effector functionFc-engineeringneutralizing antibodyVenezuelan equine encephalitis virus (VEEV)

Identifiers

PMID38170638
PMCPMC10766394
OpenAlexW4390535144

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.